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A case study of eight type 2 diabetic stage 4  
chronic kidney disease patients showing 
lower glycemic variability with faster-acting 
insulin aspart as compared to insulin aspart
ABSTRACT
Background. Peaks and nadirs of blood glucose level 
varying daily in a person is referred to as glycemic 
variability (GV). GV associated with diabetics has been 
recently linked to cardiovascular disorders (CVD) or even 
chronic kidney disease (CKD) progression. Faster-acting 
insulin aspart is the latest ultra-rapid acting bolus insulin 
which has shown much lesser intra- and inter-patient 
variability as compared to conventional bolus insulin. 
Material and methods. However, inadequate data ex-
ist regarding GV in patients with advanced stages of 
CKD. Hence, with this objective, the present case study 
was undertaken with eight patients divided into two 
equal groups, wherein faster-acting insulin aspart and 
insulin aspart were used as the boluses, respectively. 
Continuous glucose monitoring data of the patients 
were taken for the initial four days to calculate mean 
amplitude of glycemic excursion (MAGE) of the total 
four days for each individual (mmol/L) to see the dif-
ference in GV. A value of > 3.607 mmol/L (65 mg/dL) 
was considered to be statistically significant. 
Results. In this case study of eight stage 4 CKD type 2 
diabetic patients, statistically significant lower GV 
was observed in the faster-acting insulin aspart arm 
when compared with the insulin aspart arm. The p-
value was 0.0004 in unpaired t-test and < 0.05 for U 
in Mann-Whitney U test after ruling out the baseline 
confounding factors. 
Conclusions. This study confirms the stable pharma-
cokinetic and dynamic properties of faster-acting insu-
lin aspart and subsequent studies with larger number 
of patients are required for a conclusive outcome. (Clin 
Diabetol 2019; 8, 6: 284–291)
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Introduction
Constant hyperglycemia and bursts of prandial 
glycemic surges can cause complications in diabetes 
mellitus (DM) as well as in stress hyperglycemia [1, 
2]. Postprandial spikes in blood sugar, along with epi-
sodes of hypoglycemia, are responsible for an alarming 
increase in cardiovascular events in DM [2]. Glycemic 
variability (GV) comprises these events; thus, mini-
mizing GV will suspend future cardiovascular events. 
Addressing GV emerges as a target to be pursued in 
clinical procedures to reduce the mean blood glucose, 
as GV is now considered to be an independent risk 
factor in diabetics for cardiovascular disease (CVD) 
[3]. Contemporary DM treatment modalities with 
glucagon-like peptide-1-based remedy, newer insulin, 
newer insulin pumps, bariatric surgery and newer oral 
anti-diabetic molecules considerably decrease GV [4].
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The mean amplitude of glycemic excursion (MAGE) was 
intended to encapsulate repast-time related glucose 
excursions. GV implies to the swings in blood glucose 
level seen in a person daily. Decreased or missing glyce-
mic auto-modulation or deficits of insulin accessibility 
are hypothesized to be the etiological causes for these 
glycemic ridges swings [4]. Intermittent high blood glu-
cose exposure rather than constant high blood glucose 
exposure has been shown to have deleterious effect in 
various experimental studies [5]. 
GV indices derived from continuous glucose moni-
toring (CGM) are mean ± standard deviation, J index, 
coefficient of variance, low blood glucose index, high 
blood glucose index, average daily risk range, MAGE, 
mean of daily differences and continuous overall net 
glycemic action [4]. 
Faster-acting insulin aspart is the latest ultra-rapid 
acting bolus insulin derived by substituting amino acid 
proline by aspartic acid in position B28 and adding inac-
tive ingredients L-arginine, niacinamide and others and 
appearing in circulation after 2.5 minutes of administra-
tion [6]. But the data of this insulin in advanced chronic 
kidney disease (CKD) patients is limited, and therefore, 
the present case study was undertaken to get newer 
insights into the use of faster-acting insulin aspart as 
compared to insulin aspart in relation to the difference 
in MAGE, as MAGE or rather GV has been described as 
an independent marker of CVD [3]. 
Case presentation
We analyzed the clinical records of MAGE of eight 
type 2 diabetic CKD stage 4 (as calculated by Chronic 
Kidney Disease Epidemiology Collaboration equation) 
patients. A total data of thirty seven patients were 
searched who were meeting the primary criteria of 
basal-bolus insulin regimen with eGFR (estimated 
glomerular filtration rate) less than 30 ml/min/1.73 m2 
without any oral anti-diabetic drugs and out of them 
only eight finally meet the full inclusion criteria. All the 
patients had to meet the pre-specified inclusion criteria 
— type 2 diabetics who previously faced either severe 
or mild to moderate hypoglycemia on regular human 
insulin treatment, age more than 55 years; giving in-
formed, written consent; MAGE calculated from CGM 
data; HbA1c of 7.5–9%; estimated glomerular filtration 
rate (eGFR) 15–30 ml/min/1.73 m2; duration of diabe-
tes for more than 10 years; all on basal-bolus insulin 
regimen (basal component being insulin glargine given 
at a dose to achieve a fasting value of 130 mg/dl); no 
orally administered agents; and bolus was either insulin 
aspart or faster-acting insulin aspart given just before 
meals. The baseline characters of all patients are given 
in Table 1. Then they were divided into two groups 
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depending on the types of hypoglycemia faced by each 
patient namely those with severe hypoglycemia were 
treated with faster-acting aspart insulin and those who 
had mild to moderate hypoglycemia were treated with 
aspart insulin as the bolus insulin. The mean baseline 
values of the total population were HbA1c 8.22%, age 
64.75 years, duration of diabetes 11.87 years and eGFR 
25.12 ml/min/1.73 m2. The 95% confidence interval 
(CI) and standard deviation (SD) values of the above 
baseline characters are given in Table 2.
Materials and methods
In the present case study, we analyzed the CGM 
data (performed with Medtronic iPro2® machine) 
of the patients for the initial four days to calculate 
MAGE (mmol/L) for each individual as measured by 
the software EasyGV Version 9.0.R2 (Nathan R Hill — 
Copyright University of Oxford 2010–2016) so as to 
see the differences in GV. A value of more than 3.607 
mmol/L (65 mg/dL) was considered to be significantly 
high, indicating high GV as has been found previously 
[7]. All the methods were followed as per directions 
laid down in the declaration of Helsinki. 
A CGM sensor was attached to the subcutaneous 
fat tissue of these patients and adjusted by the standard 
Medtronic iPro2 working principles. While wearing the 
CGM, the patients checked their blood glucose levels 
with a self-monitoring blood glucose device, 4 times 
a day. The data of the first 4 days from the CGM of 
each patient was analyzed with the above-mentioned 
software to calculate MAGE as well as eight other GV 
indices, namely SD, mean, continuous overall net gly-
cemic action, mean of daily differences, average daily 
risk range, J index, low blood glucose index and high 
blood glucose index. After analyzing data, patients 
were divided into two groups (4 patients each). The 
first group used only aspart as bolus insulin while the 
other group used faster-acting aspart as bolus insulin. 
Unpaired T-test and Mann-Whitney U-test were ap-
plied to compare the two groups with regard to each 
para meter that could have affected the final MAGE 
outcome, namely baseline HbA1c, age, duration of 
Table 2. 95% confidence interval (CI), standard deviation and mean values of baseline characters
MAGE  
[mmol/L]
HbA1c  
(%)
eGFR  
[ml/min/1.73 m2]
Duration of  
diabetes (years)
Age  
(years)
Standard deviation, d 1.37 0.40 3.82 1.26 3.38
95% CI 4.87 ± 0.95  
(± 19.60%)
8.22 ± 0.28  
(± 3.42%)
25.12 ± 2.64  
(± 10.54%)
11.87 ± 0.87  
(± 7.40%)
64.75 ± 2.34  
(± 3.62%)
Average (mean values) 4.87 8.22 25.12 11.87 64.75
MAGE — mean amplitude of glucose excursion; HbA1c — glycated hemoglobin; eGFR — estimated glomerular filtration rate
diabetes, and eGFR. Baseline Pearson correlation and 
Spearman Rank correlation were also calculated [soft-
ware: Wessa P. (2017). Pearson Correlation (v1.0.13) in 
(Free Statistics Software (v1.2.1), Office for Research 
Development and Education] was used to determine 
any baseline statistical significance which might affect 
the MAGE (as MAGE was the dependable variable here). 
Results 
The baseline correlation equations using both 
Pearson’s formula and Spearman Rank formula (Table 3) 
confirm no statistical significance with MAGE as de-
pendable variable. Here, the independent variables 
were HbA1c (p-value 0.347 for Pearson formula), age 
(p-value 0.344 for Pearson formula), duration of dia-
betes (p-value 0.188 for Pearson formula) and eGFR 
(p-value 0.79 for Pearson formula). 
After dividing the MAGE calculated and other 
GV parameters calculated in two groups, we applied 
Unpaired T-test and Mann-Whitney U test (Table 4) to 
see the baseline statistical differences between the two 
groups in terms of HbA1c, age, duration of diabetes 
and eGFR which might have affected the final MAGE 
outcome. We found all the parameters to be statistically 
non-significant in both the tests, reducing the bias at 
baseline parameters for the outcome.
Further, on applying Unpaired T-test and Mann-
-Whitney U test in MAGE outcome (Table 5) and Un-
paired T-test on other eight GV parameters (Table 6) be-
tween the two groups, only MAGE showed statistically 
significant results in Unpaired T-test (p-value 0.0004) as 
well as in Mann-Whitney U test (p-value 0.012). 
As SD between groups can cause significant 
changes in the MAGE outcome, we also performed 
both Unpaired T-test and Mann-Whitney U-test be-
tween the two groups taking their SD values (Table 7) 
and found both to be statistically non-significant, 
ruling out the probability of SD to be a confounding 
factor in the final MAGE outcome analysis between 
the two groups.
The figures of CGM data of one patient from each 
group are given in Figure 1 and Figure 2 and also the 
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presentation of CGM, postprandial excursions can 
be surveyed using the zone under the curve and the 
trapezoidal strategy; the determination of MAGE is 
operator-controlled and not unambiguously chara-
cterized [14]. Among non-diabetic patients having 
coronary artery disease (CAD), MAGE was found to 
be associated with cardiovascular events [7]. However, 
in type 2 diabetic patients, MAGE, as one of the GV 
parameter, was found to be significantly associa-
ted with CAD, CKD and stroke(p-value for all three 
< 0.01). MAGE also showed significant correlation to 
eGFR and urine albumin:creatinine ratio (p-value for 
both < 0.03) [15]. 
Faster-acting insulin aspart is the fastest ultra-rapid 
acting bolus insulin derived by substituting an amino 
acid from the regular insulin chain at B28 position by 
aspartic acid with the addition of few ingredients like 
L-arginine and niacinamide. It reaches bloodstream 
by 2.5 minutes with stable pharmacokinetic and 
pharmacodynamic properties and is suitable for use 
even post-meals for prandial control of glucose [6]. 
Niacinamide causes faster absorption of the insulin 
from subcutaneous tissue [6]. The data of this insulin 
in stage 4 CKD patients is sparse, and therefore, the 
present case study has provided some insight into this 
aspect. However, larger trials are required for further 
inference. Another switchover study on faster-acting 
insulin aspart showed significant reduction in nocturnal 
hypoglycemia risk when compared to human regular 
insulin by 80% as well as significant reduction in MAGE 
value over four days [16]. Due to the ultra-rapid onset of 
action, the risk seems to be reduced for hypoglycemia 
[17] as well there is documented 74% greater early glu-
cose reductions when compared to aspart insulin [18]. 
These properties of faster-acting aspart make it an ideal 
candidate to lower GV with least risk of hypoglycemia 
when compared to aspart insulin.
Table 3. Correlation analysis for MAGE as dependable variable against independent variables duration of diabetes, HbA1c, 
age and eGFR 
Pearson correlation (dependable variable MAGE) HbA1c eGFR Age Duration of  
diabetes
T-test 1.01 –0.27 –1.02 1.48
p-value (2 sided) 0.34 0.79 0.34 0.18
95% CI of correlation [–0.43, 0.85] [–0.75, 0.64] [–0.85, 0.43] [–0.29, 0.89]
Spearman rank correlation  
(dependable variable MAGE)
Rho 0.54 0.17 –0.35 0.18
2-sided p-value 0.17 0.68 0.38 0.66
MAGE — mean amplitude of glycemic excursions; HbA1c — glycated hemoglobin; eGFR — estimated glomerular filtration rate; CI — confidence interval
average CGM values of each group is described in Table 8 
which also shows no significant difference between the 
average CGM values between two groups. 
Discussion
The postprandial glycemic excursions in glucose 
level, as well as daily glucose variations, lead to GV [4]. 
The event of different microvascular and macrovascular 
complications in diabetes is ascribed to the dysglycemia 
(peaks and nadirs) seen in a diabetic patient occur-
ring more than the accepted physiological variations 
for that individual [8]. Two unifying hypotheses have 
been put forward that accounts for GV, uncontrolled 
protein glycation termination products and initiation 
of oxidative stress, resulting in vascular complications 
[4]. There is a significant relationship between GV and 
the increased occurrence of hypoglycemia [9]. HbA1c 
reflects only 8% of severe hypoglycemia; hence, it is 
a poor marker [10]. But GV can predict around 40 to 
50% of future hypoglycemic episodes [4]. Investiga-
tions have demonstrated that GV, related to extreme 
hypoglycemia, could be deleterious to both diabetics as 
well as non-diabetic patients in intensive care units [11]. 
Besides CVD, the risk of retinopathy is also increased 
with GV. The contribution of GV and instability rather 
than the absolute glucose values have been shown to 
be responsible for CV mortality as well as for all-cause 
mortality in elderly type 2 DM patients [12]. Addition-
ally, in 1504 acute ischemic stroke patients with diabe-
tes, it was observed that even after adjusting baseline 
HbA1c, the functional outcome after 3 months was 
poorer in patients having increasing glucose level range 
quartile (used as GV marker). CKD has been shown to 
be a major contributor to GV [13].
Among the various methods used to determine 
GV, MAGE is an acceptable tool, but it has some 
disadvantages, e.g., connection with SD with the 
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Table 4. Unpaired T-test and Mann-Whitney U test between various parameters that might affect the MAGE outcome 
between two groups (one using faster-acting insulin aspart and the other using insulin aspart)
Unpaired T-test for B/L HbA1c Mean SD 95% CI p-value
Faster-acting-aspart group 8.12 0.54 –0.58 to 0.98 0.55
Aspart group 8.32 0.34
Unpaired T-test for B/L eGFR
Faster-acting-aspart group 25.75 3.86 –8.78 to 6.28 0.69
Aspart group 24.5 4.8
Unpaired T-test for B/L age
Faster-acting-aspart group 65.75 2.63 –8.45 to 4.45 0.47
Aspart group 63.75 4.57
Unpaired T-test for B/L duration of diabetes
Faster-acting-aspart group 11.5 0.58 –1.67 to 3.17 0.47
Aspart group 12.25 1.89
Mann-Whitney U-test For HbA1c For age For EGFR For duration of diabetes
U value 7 8.5 11 9
Critical value of U at p < 0.5 2 2 2 2
Statistical significance of U Non significant Non significant Non significant Non significant
Z-score 1.04 0.73 –0.20 –0.62
p-value of Z 0.29 0.46 0.83 0.52
Statistical significance of Z-score Non significant Non significant Non significant Non significant
HbA1c — glycated hemoglobin; eGFR — estimated glomerular filtration rate; SD — standard deviation; CI — confidence interval
Table 5. Unpaired T-test values and Mann-Whitney U test for MAGE values of the two groups
Unpaired T-test Mean SD 95% CI p-value
Faster-acting insulin aspart group 3.66 0.63 1.47 to 3.38 0.0004*
Insulin aspart group 6.08 0.66
Mann-Whitney U-test
U value 0
Critical value of U at p < 0.5 2
Statistical significance of U Significant
Z-score 2.50
p-value of Z 0.01*
Statistical significance of Z-score Significant
*Extremely statistically significant for unpaired T-test and statistically significant for Mann-Whitney U test; CI — confidence interval; SD — standard deviation; 
MAGE — mean amplitude of glucose excursion
Our case study revealed that faster-acting insulin 
aspart (as compared to insulin aspart) had a lower GV, 
indicated by MAGE outcome from CGM in advanced 
stage 4 CKD diabetic patients, even after excluding 
confounding factors of baseline HbA1c, age, duration 
of diabetes, eGFR and SD between the two groups as 
projected by the p-values of 0.0004 in unpaired t-test 
and < 0.05 for U in Mann-Whitney U test. Hence, 
faster-acting insulin aspart can be used therapeutically 
to achieve acceptable GV in most diabetic patients with 
CKD, as it showed better results in patients in stage 
4 of CKD. Lower GV should clinically produce lower 
rates of hypoglycemic risk, which should be our tar-
get to effectively counter glycemia in advanced CKD 
patients. 
Conclusion
In this case study, we found that faster-acting in-
sulin aspart was associated with statistically significant 
lower GV, as compared to insulin aspart, in patients 
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Table 6. Unpaired T-test of glycemic variability parameters other than MAGE in two groups
Mean SD 95% CI p-value
SD
Faster-acting insulin aspart 2.34 0.74 –0.89 to 0.93 0.96
Insulin aspart 2.36 0.08
Mean
Faster-acting-aspart group 8.58 0.64 –0.79 to 1.48 0.48
Aspart group 8.92 0.67
Continuous overall net glycemic action
Faster-acting-aspart group 8.10 0.44 –1.37 to 1.02 0.73
Aspart group 7.93 0.87
High blood glucose index
Faster-acting-aspart group 6.94 2.28 –2.93 to 3.30 0.88
Aspart group 7.13 1.13
Average daily risk range
Faster-acting-aspart group 16.43 4.84 –0.33 to 12.8 0.05
Aspart group 22.66 2.32
J index
Faster-acting-aspart group 38.90 6.74 –7.72 to 12.68 0.57
Aspart group 41.38 4.90
Low blood glucose index
Faster-acting-aspart group 0.89 0.29 –0.90 to 1.35 0.64
Aspart group 1.11 0.87
Mean of daily differences
Faster-acting-aspart group 2.31 0.65 –1.51 to 0.23 0.12
Aspart group 1.67 0.28
SD — standard deviation; CI — confidence interval
Table 7. Unpaired T-test and Mann-Whitney U-test between the two groups for SD
Unpaired T-test Mean SD 95% CI p-value
Faster-acting insulin aspart group 42.18 13.41 16.19 to 16.83 0.96
Insulin aspart group 42.50 1.47
Mann-Whitney U-test
U value 7
Critical value of U at p < 0.5 2
Statistical significance of U Non significant
Z-score 1.04
p-value of Z 0.29
Statistical significance of Z-score Non significant
SD — standard deviation; CI — confidence interval
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Table 8. CGM values averaged over the four days in two groups
Patient serial number CGM value averaged for four days Bolus insulin group Average value of CGM for each group
1 156.21 Faster-acting aspart 
group
160.66
2 160.32
3 177.33
4 148.79
5 163.47 Aspart group 154.47
6 138.85
7 162.91
8 152.63
Figure 1. CGM data of one patient on aspart insulin
Figure 2. CGM data of one patient on faster-acting aspart insulin
with advanced CKD. Recently, GV has emerged as a 
target objective in diabetes holistic management due to 
its association with CVD and CKD progression. Finally, 
this study confirms the stable pharmacokinetic and 
dynamic properties of faster-acting insulin aspart, and 
future studies involving larger number of patients can 
help draw a conclusion. 
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